Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Suzhou Abogen Biosciences Co., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07583953CT.gov An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07245901CT.gov Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07097948CT.gov Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033 | — | Not Yet Recruiting | — | — | — |
NCT06975293CT.gov STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | — | Recruiting | — | — | — |
NCT05798533CT.gov Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | — | Unknown | — | — | — |
NCT06117566CT.gov A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05576961CT.gov Safety and Efficacy of RX-af01 Combined With PD-1 Antibody | — | Unknown | — | — | — |
NCT05369286CT.gov A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05165849CT.gov A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT05173142CT.gov A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | — | Completed | — | — | — |
Show 8 more trialsShow fewer
NCT05167071CT.gov HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | — | Active Not Recruiting | — | — | — |
NCT05149027CT.gov A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors | — | Unknown | — | — | — |
NCT07392736CT.gov A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. | — | Recruiting | — | — | — |
NCT04991506CT.gov A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT04727164CT.gov Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab | — | Unknown | — | — | — |
NCT03810339CT.gov Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT03879057CT.gov Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors | — | Unknown | — | — | — |
NCT02857166CT.gov Study of JS001 in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Toripalimab (this asset) | Suzhou Abogen Biosciences Co., Ltd. | P2 | B · 60 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Toripalimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | BB · 67 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Toripalimab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/toripalimab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →